Amarantus Bioscience Holdings Inc (AMBS)

[WarpCore61]

Risk, I've wondered the same thing. But if you remember the investors conference call back from April 16, 2013 where Jason Napadano asked Gerald how they were able to obtain LymPro so cheaply, Gerald went into great detail in his explanation, and it made a lot of sense. The link I posted to that audio file is no longer active.

I imagine the scenario with Eltoprazine is somewhat similar to that described with licensing LymPro from Provista. Lowe knew about the drug and understood why it was not being moved forward for so long. As with LymPro, the company found out about Eltoprazine through their connections, and were able to work out an potentially lucrative licensing deal that allowed the company to move the drug testing forward.

Even with LymPro, Gerald never went into much detail until asked directly by Jason during a conference call. Although I believe Gerald has covered some of this in one of his recent presentations, perhaps we can get Jason to ask Gerald about Eltoprazine at the next opportunity and answer some of our questions.

I was going to post a new link to the applicable portion of that conference call regarding acquisition of LymPro, but the file is on another computer and I can't retrieve it until tomorrow. If anyone is interested in hearing the related LymPro story again, I'll make the effort to retrieve the audio file and post the link. It's likely a similar situation existed with Eltoprazine.

Also, from what I've learned about how biotech's work since becoming an Amarantus shareholder, it seems some biotech's would rather shelve a project when funding or the regulatory environment is not suitable for continued development of the asset, rather than sell or license the asset to a competitor. The strategy would be to return to the asset at a later time and pick up where development stopped. At some point when it becomes clear this strategy will take more time than expected, the company may then be more open to licensing agreements with other biotech companies, especially those who seek out the asset through their contacts who may be former researchers with the company holding the asset. At that point it might be more about established relationships and trust and the desire to move the asset forward, than simply total dollars.

Sound reasonable?